Ocugen, Inc.

OCGN

NASDAQ

Healthcare

Biotechnology

Malvern, PA, US95 employeesocugen.com

$1.78

-0.01(-0.28%)

Mkt Cap $585M

$0.58

$2.48

52-Week Range

At a Glance

AI-generated

Ocugen, Inc.

8-K

Ocugen, Inc. announced topline 12-month data from the Phase 2 ArMaDa clinical trial of OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, with the optimal (medium) dose showing a statistically significant 31% reduction in lesion growth versus control (lesions ≥2.5 mm² and ≤17.5 mm², N=39). The company scheduled a conference call and webcast for March 24, 2026, at 8:00 a.m. EDT to discuss the data.

$585M

Market Cap

$5M

Revenue

-$71M

Net Income

Employees95

Fundamentals

How The Business Makes Money

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Feb 8, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment

Financial Results

Mar 3, 2026

of this Report, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang

Material Agreement

Jan 20, 2026

Entry into a Material Definitive Agreement. On January 20, 2026, Ocugen, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agree

Regulation FD

Mar 23, 2026

of this Form 8-K, including Exhibits 99.1 , 99.2 and 99.3 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the

Other Event

Mar 19, 2026

Other Events. As previously disclosed, in August 2025, Ocugen, Inc. (“Ocugen”) closed a registered direct offering, pursuant to a securities purchase agreement

Peer Companies

Company	Price	Change	Market Cap	P/E
ALMSAlumis Inc. Common Stock	$23.42	+3.04%	$2.9B	-10.1
RAPTRAPT Therapeutics, Inc.	$58.01	+0.00%	$959M	-14.8
OMEROmeros Corporation	$10.94	-9.44%	$776M	-5.8
CMPXCompass Therapeutics, Inc...	$5.46	+0.55%	$755M	-14.0
LXRXLexicon Pharmaceuticals, ...	$1.59	-2.74%	$676M	-11.8
ADCTADC Therapeutics S.A.	$3.80	+0.03%	$483M	-4.3
FULCFulcrum Therapeutics, Inc...	$8.06	+7.75%	$436M	-5.8
LCTXLineage Cell Therapeutics...	$1.56	-1.57%	$390M	—

Analyst View

Company Profile

CIK0001372299

ISINUS67577C1053

CUSIP67577C105

Phone484 328 4701

Address263 Great Valley Parkway, Malvern, PA, 19355, US

SEC EDGAR